Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Granules India Limited ( (IN:GRANULES) ).
Granules India Limited announced that its wholly owned subsidiary, Granules Life Sciences, has successfully completed a U.S. FDA inspection of its Shamirpet, Telangana oral solid dosage manufacturing facility, receiving a Voluntary Action Indicated classification. The cGMP and pre-approval inspection, conducted in December 2025, concluded with no recommended regulatory action, reinforcing the company’s multi-site manufacturing capabilities for approved products and underscoring its strategic emphasis on quality as a core operational pillar.
Management highlighted that the outcome strengthens Granules India’s finished dosage platform and supports greater flexibility in supplying global markets from multiple sites. The VAI classification and closure of the inspection are expected to enhance regulatory confidence in the company’s manufacturing network, potentially improving its competitive positioning in regulated pharmaceutical markets and providing additional assurance for customers and stakeholders regarding product quality and compliance.
More about Granules India Limited
Granules India Limited is a Hyderabad-based pharmaceutical company that operates through subsidiaries such as Granules Life Sciences Private Limited. The group focuses on manufacturing oral solid dosage formulations and finished dosages, serving regulated markets including the U.S. through facilities that adhere to current Good Manufacturing Practice standards.
Average Trading Volume: 51,949
Technical Sentiment Signal: Buy
Current Market Cap: 151.2B INR
Learn more about GRANULES stock on TipRanks’ Stock Analysis page.